Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Teledyne entered the second half of 2026 with record quarterly orders, sales and operating profit, 9.8% year-over-year sales growth, 20.8% non-GAAP EPS growth, a 23.4% non-GAAP operating margin, approximately $5.0 billion of funded backlog and leverage reduced to 1.1 times. These indicators support a favorable operating outlook, particularly in digital imaging, space, defense and unmanned systems. The pending approximately $1.1 billion cash acquisition of Varex Imaging adds a complementary X-ray technology platform but introduces regulatory, closing, financing and integration uncertainty through early 2027.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026
Low · most bearish analyst$640.00
Mean target$757.25
High · most bullish analyst$877.00
Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$640.0017%

Backlog declines from the second-quarter benchmark, fiscal-2026 earnings guidance is reduced, or regulatory and integration complications delay or impair the Varex transaction. Weaker demand in digital imaging or defense-related applications would amplify the downside because those markets were important contributors to recent growth.

Base CaseCentral scenario
$757.2558%
Matches the consensus mean

Teledyne delivers within its fiscal-2026 non-GAAP diluted EPS guidance of $24.45 to $24.65, converts backlog without material margin deterioration, and completes Varex in the company-stated early-2027 period.

Bull CaseUpside scenario
$877.0025%

Record orders and the approximately $5.0 billion funded backlog convert into sustained growth, digital-imaging demand remains strong across space, airborne, marine and counter-unmanned applications, margins continue expanding, and Varex closes on schedule with its complementary X-ray portfolio strengthening Teledyne's healthcare and industrial-imaging position.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Second-quarter 2026 results established company records for quarterly orders, sales and operating profit; sales increased 9.8% and non-GAAP diluted EPS increased 20.8% year over year.
  • Approximately $5.0 billion of funded backlog provides demand visibility, with management identifying significant growth in space, airborne, marine-unmanned and counter-unmanned imaging applications.
  • Second-quarter free cash flow was $284.7 million and the consolidated leverage ratio declined to 1.1 times after repayment of $450 million of gross debt.
Sign in / Sign up to read more
Key Investment Risks
  • The approximately $1.1 billion Varex acquisition remains subject to stockholder approval, regulatory approvals and other closing conditions and is not expected to close until early 2027.
  • Varex creates execution exposure involving integration, customer and employee retention, synergy realization, transaction costs and potentially weaker-than-expected acquired operating results.
  • Recent organic strength was greatest in Digital Imaging and defense-oriented space and unmanned applications, creating sensitivity to program timing, government demand and market-specific slowdowns.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.